JP2024503482A5 - - Google Patents

Info

Publication number
JP2024503482A5
JP2024503482A5 JP2023543164A JP2023543164A JP2024503482A5 JP 2024503482 A5 JP2024503482 A5 JP 2024503482A5 JP 2023543164 A JP2023543164 A JP 2023543164A JP 2023543164 A JP2023543164 A JP 2023543164A JP 2024503482 A5 JP2024503482 A5 JP 2024503482A5
Authority
JP
Japan
Application number
JP2023543164A
Other languages
Japanese (ja)
Other versions
JP2024503482A (ja
JPWO2022155476A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012530 external-priority patent/WO2022155476A1/en
Publication of JP2024503482A publication Critical patent/JP2024503482A/ja
Publication of JPWO2022155476A5 publication Critical patent/JPWO2022155476A5/ja
Publication of JP2024503482A5 publication Critical patent/JP2024503482A5/ja
Pending legal-status Critical Current

Links

JP2023543164A 2021-01-15 2022-01-14 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用 Pending JP2024503482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163138221P 2021-01-15 2021-01-15
US63/138,221 2021-01-15
PCT/US2022/012530 WO2022155476A1 (en) 2021-01-15 2022-01-14 Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use

Publications (3)

Publication Number Publication Date
JP2024503482A JP2024503482A (ja) 2024-01-25
JPWO2022155476A5 JPWO2022155476A5 (https=) 2025-01-22
JP2024503482A5 true JP2024503482A5 (https=) 2025-01-22

Family

ID=80222188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543164A Pending JP2024503482A (ja) 2021-01-15 2022-01-14 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用

Country Status (8)

Country Link
US (1) US20240293532A1 (https=)
EP (1) EP4277656A1 (https=)
JP (1) JP2024503482A (https=)
KR (1) KR20230132816A (https=)
CN (1) CN117412769A (https=)
AU (1) AU2022208035A1 (https=)
CA (1) CA3205052A1 (https=)
WO (1) WO2022155476A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO2010044921A2 (en) * 2008-06-03 2010-04-22 Vaxin Inc. Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens
CN102549152B (zh) * 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 基于腺病毒的载体
KR102104650B1 (ko) * 2011-03-21 2020-04-24 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제
MX2022009460A (es) * 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
WO2021160346A1 (en) * 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
MX2022015132A (es) * 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.

Similar Documents

Publication Publication Date Title
JP2024530047A5 (https=)
JP2024539609A5 (https=)
BR102022025291A2 (https=)
JP2024503482A5 (https=)
CL2025004057A1 (es) Intermedio inhibidor de dpp1, y método de preparación para el mismo y uso del mismo en medicamentos.
CL2025002729A1 (es) Válvulas de sifón neumáticas y cámaras de reacción para el análisis de muestras
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022001779U2 (https=)
BY13169U (https=)
CN307044797S (https=)
CN307044384S (https=)
CN307045559S (https=)
CN307044355S (https=)
CN307044321S (https=)
CN307045889S (https=)
CN307046712S (https=)
CN307046845S (https=)
BY23966C1 (https=)